Background: Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios.
Methods: We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up).
Results: Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8+ T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic.
Specifically, terminally exhausted effector CD8+ T cells (T-betdim/-EomeshiPD1hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8+ T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10.
Conclusions: Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention.
Searching for signatures of positive selection in cytochrome b gene associated with subterranean lifestyle in fast-evolving arvicolines (Arvicolinae, Cricetidae, Rodentia)
Background: Mitochondrial genes encode proteins involved in oxidative phosphorylation. Variations in lifestyle and ecological niche can be directly reflected in metabolic performance. Subterranean rodents represent a good model for testing hypotheses on adaptive evolution driven by important ecological shifts.
Voles and lemmings of the subfamily Arvicolinae (Rodentia: Cricetidae) provide a good example for studies of adaptive radiation. This is the youngest group within the order Rodentia showing the fastest rates of diversification, including the transition to the subterranean lifestyle in several phylogenetically independent lineages.
Results: We evaluated the signatures of selection in the mitochondrial cytochrome b (cytB) gene in 62 Arvicolinae species characterized by either subterranean or surface-dwelling lifestyle by assessing amino acid sequence variation, exploring the functional consequences of the observed variation in the tertiary protein structure, and estimating selection pressure. Our analysis revealed that:
(1) three of the convergent amino acid substitutions were found among phylogenetically distant subterranean species and
(2) these substitutions may have an influence on the protein complex structure
(3) cytB showed an increased ω and evidence of relaxed selection in subterranean lineages, relative to non-subterranean, and
(4) eight protein domains possess increased nonsynonymous substitutions ratio in subterranean species.
Conclusions: Our study provides insights into the adaptive evolution of the cytochrome b gene in the Arvicolinae subfamily and its potential implications in the molecular mechanism of adaptation. We present a framework for future characterizations of the impact of specific mutations on the function, physiology, and interactions of the mtDNA-encoded proteins involved in oxidative phosphorylation.
Screening of wheat genotypes for the presence of common bunt resistance genes
Common bunt is known to cause grain yield and quality losses in wheat due to bunt ball formation and infestation of the grain. The aim of this study is to identify for sources of resistance to common bunt in wheat genotypes using phytopathological and molecular methods. In general, studied 60 Kazakh and foreign wheat genotypes were found 15 samples with the Bt9, Bt8 and Bt11 genes. Carriers of the Bt10 gene include the five varieties.
The four resistance genes, Bt8, Bt10, Bt11, Bt9, and Bt10 were identified in the Karasai variety. Phytopathological and molecular screening of Kazakh and foreign wheat genotypes selected 18 with genes for resistance to the disease. According to evaluation on an artificial infection 19 varieties showed an immune type of reaction.
These varieties will be used in breeding programs as donors to create resistant varieties against the common bunt. Thus, approaches can reduce the level of fungicides use and the most effective method to control the common bunt.
Genetic Mutations Associated with Pierre Robin Syndrome/Sequence: A Systematic Review
Pierre Robin syndrome/sequence (PRS) is associated with a triad of symptoms that includes micrognathia, cleft palate, and glossoptosis that may lead to respiratory obstruction. The syndrome occurs in 2 forms: nonsyndromic PRS (nsPRS), and PRS associated with other syndromes (sPRS). Studies have shown varying genetic mutations associated with both nsPRS and sPRS.
The present systematic review aims to provide a comprehensive collection of published literature reporting genetic mutations in PRS. Web of Science, PubMed, and Scopus were searched using the keywords: “Pierre Robin syndrome/sequence AND gene mutation.”
- The search resulted in 208 articles, of which 93 were excluded as they were duplicates/irrelevant.
- The full-text assessment led to the further exclusion of 76 articles. From the remaining 39 articles included in the review, details of 324 cases were extracted. 56% of the cases were sPRS, and 22% of the cases were associated with other malformations and the remaining were nsPRS.
- Genetic mutations were noted in 30.9% of the 300 cases. Based on the review, SOX9 was found to be the most common gene associated with both nsPRS and sPRS. The gene mutation in sPRS was specific to the associated syndrome.
- Due to the lack of original studies, a quantitative analysis was not possible. Thus, future studies must focus on conducting large-scale cohort studies.
- Along with generating data on genetic mutation, future studies must also conduct pedigree analysis to assess potential familial inheritance, which in turn could provide valuable insights into the etiopathogenesis of PRS.
HTLV-I/II p19 Antigen ELISA Kit |
|||
DEIA10160 | Creative Diagnostics | 96T | EUR 1354.5 |
Description: cell cultures |
HTLV-I p24 Antigen |
|||
GWB-DF0617 | GenWay Biotech | 1 mg | Ask for price |
HTLV I p19 Antibody |
|||
GWB-7118BB | GenWay Biotech | 0.025 mg | Ask for price |
HTLV-I p24 core recombinant antigen |
|||
00204-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HLTV-I p24 core recombinant antigen. |
HTLV-I p24 core recombinant antigen |
|||
00204-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HLTV-I p24 core recombinant antigen. |
HTLV-1 p24, C-terminal His-tag |
|||
REC32063-100 | The Native Antigen Company | 0.1 | EUR 496.27 |
Description: HTLV-1 p24, C-terminal His-tag, purified by immobilized metal affinity chromatography, ion exchange chromatography and dialysis. |
HTLV-1 p24, C-terminal His-tag |
|||
REC32063-500 | The Native Antigen Company | 0.5 | EUR 2109.16 |
Description: HTLV-1 p24, C-terminal His-tag, purified by immobilized metal affinity chromatography, ion exchange chromatography and dialysis. |
HTLV-2 p24, C-terminal His-tag |
|||
REC32075-100 | The Native Antigen Company | 0.1 | EUR 463.1 |
Description: Human T-lymphotropic virus 2 (HTLV-2) p24 gag protein produced in E. Coli. There is evidence for dimer and higher oligomer formation. |
OPMA04682-1MG - HTLV-I p24 Antigen Protein |
|||
OPMA04682-1MG | Aviva Systems Biology | 1mg | EUR 1299 |
HTLV-I Envelope Recombinant Antigen |
|||
00203-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HLTV-I envelope recombinant antigen. C-terminus of gp-46 and most of p21. |
HTLV-I Envelope Recombinant Antigen |
|||
00203-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HLTV-I envelope recombinant antigen. C-terminus of gp-46 and most of p21. |
HTLV-1 virus mosaic recombinant antigen |
|||
00205-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
HTLV-1 virus mosaic recombinant antigen |
|||
00205-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
Recombinant HTLV-1 gag p19 Protein |
|||
VAng-Lsx7388-100g | Creative Biolabs | 100 µg | EUR 2193.6 |
Description: HTLV type 1 gag p19, recombinant protein from yeast. |
HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
|||
00205-V | Virogen | 1 MG | EUR 850 |
HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
|||
00205-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. |
Recombinant Human T-cell Lymphotropic Virus-I (HTLV-I), p24 Antigen |
|||
DAG503 | Creative Diagnostics | 1mg | EUR 1444.8 |
Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Envelope Protein, Sheep Fc-Tag (HEK293) |
|||
REC31920-100 | The Native Antigen Company | 0.1 | EUR 338.08 |
Description: Recombinant human T-cell lymphotropic virus type 1 (HTLV-1) envelope protein. The protein was produced in HEK293 cells and purified from culture supernatant with a TEV cleavage site and C-terminal sheep Fc-tag. |
Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Envelope Protein, Sheep Fc-Tag (HEK293) |
|||
REC31920-500 | The Native Antigen Company | 0.5 | EUR 1190.28 |
Description: Recombinant human T-cell lymphotropic virus type 1 (HTLV-1) envelope protein. The protein was produced in HEK293 cells and purified from culture supernatant with a TEV cleavage site and C-terminal sheep Fc-tag. |
Human T-Cell Lymphotropic Virus Type 2 (HTLV-2) Envelope Protein, Sheep Fc-Tag (HEK293) |
|||
REC31921-100 | The Native Antigen Company | 0.1 | EUR 338.08 |
Description: Human T-cell Leukemia Virus 2 (HTLV-2) Envelope Protein produced in HEK293 cells with a TEV cleavable C-terminal sheep Fc-tag. The protein was purified from culture supernatant by Protein A chromatography and Hydrophobic Interaction Chromatography. The furin cleavage site in the Envelope protein was enhanced to increase the efficiency of cleavage in HEK293 cells. |
Human T-Cell Lymphotropic Virus Type 2 (HTLV-2) Envelope Protein, Sheep Fc-Tag (HEK293) |
|||
REC31921-500 | The Native Antigen Company | 0.5 | EUR 1190.28 |
Description: Human T-cell Leukemia Virus 2 (HTLV-2) Envelope Protein produced in HEK293 cells with a TEV cleavable C-terminal sheep Fc-tag. The protein was purified from culture supernatant by Protein A chromatography and Hydrophobic Interaction Chromatography. The furin cleavage site in the Envelope protein was enhanced to increase the efficiency of cleavage in HEK293 cells. |
Borrelia Afzelii Antigen |
|||
NAT41583-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Afzelii Antigen |
|||
NAT41583-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
|||
NAT41584-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
|||
NAT41584-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Brucella Abortus Antigen |
|||
NAT41599-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Brucella abortus lysate, produced by fermentation. |
Brucella Abortus Antigen |
|||
NAT41599-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Brucella abortus lysate, produced by fermentation. |
Candida Albicans Antigen |
|||
NAT41601-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Candida Albicans Antigen |
|||
NAT41601-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Canine Parvovirus Antigen |
|||
NAT41594-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Parvovirus, produced in CRFK cells. |
Canine Coronavirus Antigen |
|||
NAT41590-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Coronavirus produced in A-72 cells. |
Feline Calicivirus Antigen |
|||
NAT41595-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Feline Calicivirus produced in FC 3TG cells. |
Helicobacter Pylori Antigen |
|||
NAT41603-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Helicobacter Pylori Antigen |
|||
NAT41603-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Campylobacter Jejuni Antigen |
|||
NAT41600-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Campylobacter Jejuni Antigen |
|||
NAT41600-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Chlamydia Trachomatis Antigen |
|||
CT022-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
Neisseria Gonorrhoeae Antigen |
|||
NG01-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
Description: Homogenised lysate of pure bacteria. |
Mycoplasma Pneumoniae Antigen |
|||
MP901-1000 | The Native Antigen Company | 1.0 | EUR 1010.39 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Mycoplasma Pneumoniae Antigen |
|||
MP901-200 | The Native Antigen Company | 0.2 | EUR 270.46 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Echovirus Antigen, Recombinant |
|||
REC31776-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Echovirus Antigen, Recombinant |
|||
REC31776-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Trichomonas Vaginalis Antigen |
|||
TV01-1000 | The Native Antigen Company | 1.0 | EUR 421 |
Description: Washed & lysed suspension of whole protozoa |
Echinococcus Granulosus Antigen |
|||
NAT41602-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Echinococcus Granulosus Antigen |
|||
NAT41602-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Enterovirus Antigen, Recombinant |
|||
REC31772-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Enterovirus Antigen, Recombinant |
|||
REC31772-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Cytomegalovirus Purified Antigen |
|||
CMV-HP-100 | The Native Antigen Company | 0.1 | EUR 318.94 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
|||
CMV-HP-1000 | The Native Antigen Company | 1.0 | EUR 2096.06 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
|||
CMV-HP-500 | The Native Antigen Company | 0.5 | EUR 1279.58 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Astrovirus Antigen (Type 1) |
|||
AS02-1000 | The Native Antigen Company | 1.0 | EUR 1654.65 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Astrovirus Antigen (Type 1) |
|||
AS02-200 | The Native Antigen Company | 0.2 | EUR 442.69 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Yersinia pestis V antigen |
|||
REC32028-100 | The Native Antigen Company | 0.1 | EUR 491.53 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Yersinia pestis V antigen |
|||
REC32028-500 | The Native Antigen Company | 0.5 | EUR 2421.37 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Canine Herpes Virus Antigen |
|||
NAT41592-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Herpes virus, produced in MDCK cells. |
Canine Adenovirus 1 Antigen |
|||
NAT41587-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
Canine Adenovirus 2 Antigen |
|||
NAT41588-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
Canine Distemper Virus Antigen |
|||
NAT41591-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Distemper virus, produced in SL-29 cells. |
Norovirus GII.4 VP1 Antigen |
|||
REC31620-100 | The Native Antigen Company | 0.1 | EUR 302.36 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
|||
REC31620-1000 | The Native Antigen Company | 1.0 | EUR 1830.71 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
|||
REC31620-500 | The Native Antigen Company | 0.5 | EUR 1066.53 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Canine Parainfluenza Virus Antigen |
|||
NAT41593-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
Feline Panleukopenia Virus Antigen |
|||
NAT41597-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
Cytomegalovirus Cell Lysate Antigen |
|||
CMV-CL-100 | The Native Antigen Company | 0.1 | EUR 223.26 |
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Cytomegalovirus Cell Lysate Antigen |
|||
CMV-CL-1000 | The Native Antigen Company | 1.0 | EUR 1422.47 |
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Feline Viral Rhinotracheitis Antigen |
|||
NAT41598-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
Herpes Simplex Virus 1 Antigen |
|||
HS105-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 1 Antigen |
|||
HS105-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
|||
HS205-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
|||
HS205-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Ross River Virus Recombinant Antigen |
|||
REC31969-100 | The Native Antigen Company | 0.1 | EUR 757.8 |
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Ross River Virus Recombinant Antigen |
|||
REC31969-500 | The Native Antigen Company | 0.5 | EUR 2844.92 |
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Canine Adenovirus 1 and 2 Antigen |
|||
NAT41589-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
Hepatitis B Virus E Antigen (HBeAg) |
|||
REC31677-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus E Antigen (HBeAg) |
|||
REC31677-500 | The Native Antigen Company | 0.5 | EUR 1941.06 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
|||
REC31689-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
|||
REC31689-500 | The Native Antigen Company | 0.5 | EUR 1370.16 |
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis C Virus Core Antigen (HCcAg) |
|||
REC31693-100 | The Native Antigen Company | 0.1 | EUR 484.79 |
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Hepatitis C Virus Core Antigen (HCcAg) |
|||
REC31693-500 | The Native Antigen Company | 0.5 | EUR 1455.64 |
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Herpes Simplex Virus 1 Lysate Antigen |
|||
HS104-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
Herpes Simplex Virus 2 Lysate Antigen |
|||
HS204-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
Feline Infectious Peritonitis Virus Antigen |
|||
NAT41596-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
Legionella pneumophila antigen (native extract) |
|||
NAT41580-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Inactivated Legionella pneumophila antigen from culture. |
Streptococcus Pneumoniae Antigen, Native Extract |
|||
NAT41604-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
NAT41582-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
NAT41582-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
HTLV 1 ELISA Kit |
|||
VArk-Lsx012 | Creative Biolabs | 1 KIT | Ask for price |
Description: Used for analyzing the presence of the human T-Cell lymphotropic viruses. |
Rat HTLV-1 ELISA Kit |
|||
ERH0319 | Abclonal | 96Tests | EUR 625.2 |
Goat HTLV-1 ELISA Kit |
|||
EGTH0319 | Abclonal | 96Tests | EUR 625.2 |